142 related articles for article (PubMed ID: 6549512)
1. [Prognostic value of the results of short-term polychemotherapy by the MOPP program of Hodgkin's disease stages III and IV].
Hansz J; Burchardt K; Komarnicki M; Trepińska E; Psuja P
Pol Arch Med Wewn; 1984 Dec; 72(6):293-8. PubMed ID: 6549512
[No Abstract] [Full Text] [Related]
2. [Late results of the treatment of advanced Hodgkin's disease by the MOPP/COPP programs (chlormethine or cyclophosphamide, vincristine, procarbazine and prednisone)].
Błasińska-Morawiec M; Płuzańska A; Krykowski E; Robak T; Mrówka I
Pol Arch Med Wewn; 1991 Oct; 86(4):274-80. PubMed ID: 1813880
[TBL] [Abstract][Full Text] [Related]
3. Mopp chemotherapy in the treatment of stage IV Hodgkin's disease.
Fiacchini M; Lauria F; Mazza P; Cantore M; Gherlinzoni F; Tura S
Haematologica; 1985; 70(2):148-54. PubMed ID: 3924778
[No Abstract] [Full Text] [Related]
4. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial.
Hutchinson RJ; Fryer CJ; Davis PC; Nachman J; Krailo MD; O'Brien RT; Collins RD; Whalen T; Reardon D; Trigg ME; Gilchrist GS
J Clin Oncol; 1998 Mar; 16(3):897-906. PubMed ID: 9508171
[TBL] [Abstract][Full Text] [Related]
5. Comparison of MOPP/MOPP +/- RT vs. MOPp/ABVD +/- RT in poor prognosis Hodgkin's disease. Long-term results.
Comella P; Abate G; Fiore M; Di Finizio G; Frezza P; Scoppa G; Anania C; Coucourde F; Zarrilli D
J Chemother; 1989 Jul; 1(4 Suppl):1254-6. PubMed ID: 16312855
[No Abstract] [Full Text] [Related]
6. The role of dose and rate of administration of MOPP drugs in 97 retrospective Hodgkin's patients.
Gobbi PG; Cavalli C; Rossi A; Bertoloni D; Galeone F; Pieresca C; Grignani E
Haematologica; 1987; 72(6):523-8. PubMed ID: 3126109
[No Abstract] [Full Text] [Related]
7. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of Hodgkin's disease including the staging laparotomy].
Yosida T; Nakanisi J; Kobayasi S; Ohtake S; Ito K; Nakamura S; Hattori K; Saito Y; Tanimoto K
Rinsho Ketsueki; 1984 Jun; 25(6):827-34. PubMed ID: 6548266
[No Abstract] [Full Text] [Related]
9. [Effect of chemotherapy with C-MOPP in Hodgkin's disease in stages III B and IV B].
Larraín C; Cuchacovich M; Conte G
Rev Med Chil; 1987 Sep; 115(9):842-6. PubMed ID: 3506277
[No Abstract] [Full Text] [Related]
10. Randomised study of MOPP (mustine, Oncovin, procarbazine, prednisone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease. British National Lymphoma Investigation.
Hancock BW
Radiother Oncol; 1986 Nov; 7(3):215-21. PubMed ID: 3544084
[TBL] [Abstract][Full Text] [Related]
11. [MOPP therapy of Hodgkin's disease previously treated with MOPP].
Frau A; Montalar J
Med Clin (Barc); 1985 May; 84(19):801. PubMed ID: 3839875
[No Abstract] [Full Text] [Related]
12. [Results of the treatment of patients with Hodgkin's disease by the MOPP protocol in relation to the histological type of the disease].
Krajewska B; Dziewulska-Bokiniec A; Goszczyńska-Matysiak E; Kacprzak G
Nowotwory; 1987; 37(4):317-21. PubMed ID: 3451197
[No Abstract] [Full Text] [Related]
13. MOPP chemotherapy alone: a suitable treatment for early stages of Hodgkin's disease?
Colonna P; Andrieu JM
Lancet; 1985 May; 1(8439):1224. PubMed ID: 2860433
[No Abstract] [Full Text] [Related]
14. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial.
Longo DL; Glatstein E; Duffey PL; Young RC; Hubbard SM; Urba WJ; Wesley MN; Raubitschek A; Jaffe ES; Wiernik PH
J Clin Oncol; 1991 Jun; 9(6):906-17. PubMed ID: 2033427
[TBL] [Abstract][Full Text] [Related]
15. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie.
Raemaekers J; Burgers M; Henry-Amar M; Pinna A; Mandard A; Monfardini S; Hagenbeek A; Breed W; Carde P; Vovk M; van Hoof A; Thomas J; Noordijk E
Ann Oncol; 1997; 8 Suppl 1():111-4. PubMed ID: 9187443
[TBL] [Abstract][Full Text] [Related]
16. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
[TBL] [Abstract][Full Text] [Related]
17. Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapy.
Marcus KC; Kalish LA; Coleman CN; Shulman LN; Rosenthal DS; Canellos GP; Mauch PM
J Clin Oncol; 1994 Dec; 12(12):2567-72. PubMed ID: 7989930
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
Fermé C; Eghbali H; Meerwaldt JH; Rieux C; Bosq J; Berger F; Girinsky T; Brice P; van't Veer MB; Walewski JA; Lederlin P; Tirelli U; Carde P; Van den Neste E; Gyan E; Monconduit M; Diviné M; Raemaekers JM; Salles G; Noordijk EM; Creemers GJ; Gabarre J; Hagenbeek A; Reman O; Blanc M; Thomas J; Vié B; Kluin-Nelemans JC; Viseu F; Baars JW; Poortmans P; Lugtenburg PJ; Carrie C; Jaubert J; Henry-Amar M;
N Engl J Med; 2007 Nov; 357(19):1916-27. PubMed ID: 17989384
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
[TBL] [Abstract][Full Text] [Related]
20. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.
Longo DL; Duffey PL; DeVita VT; Wiernik PH; Hubbard SM; Phares JC; Bastian AW; Jaffe ES; Young RC
J Clin Oncol; 1991 Aug; 9(8):1409-20. PubMed ID: 1712836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
